# A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy

> **NCT00002422** · PHASE1 · COMPLETED · sponsor: **Harbor Therapeutics** · enrollment: 42 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** HE2000

## Key facts

- **NCT ID:** NCT00002422
- **Lead sponsor:** Harbor Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 42 (—)
- **Last updated:** 2009-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002422, "A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*